Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Schwartz S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Type 2 Diabetes diabetes treatment incretin-based therapies glucose control GLP-1 Cardiovascular disease Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a245e6dfd42d4d1c8328cb70f5ab4c3a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a245e6dfd42d4d1c8328cb70f5ab4c3a
record_format	dspace
spelling	oai:doaj.org-article:a245e6dfd42d4d1c8328cb70f5ab4c3a2021-12-02T00:46:20ZType 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies1178-7007https://doaj.org/article/a245e6dfd42d4d1c8328cb70f5ab4c3a2010-07-01T00:00:00Zhttps://www.dovepress.com/type-2-diabetes-mellitus-and-the-cardiometabolic-syndrome-impact-of-in-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates of type 2 diabetes mellitus, obesity, and cardiovascular disease (CVD) continue to increase at epidemic proportions. It has become clear that these disease states are not independent but are frequently interrelated. By addressing conditions such as obesity, insulin resistance, stress hyperglycemia, impaired glucose tolerance, and diabetes mellitus, with its micro- and macrovascular complications, a specific treatment strategy can be developed. These conditions can be addressed by early identification of patients at high risk for type 2 diabetes, prompt and aggressive treatment of their hyperglycemia, recognition of the pleiotropic and synergistic benefits of certain antidiabetes agents on CVD, and thus, avoiding potential complications including hypoglycemia and weight gain. Incretin-based therapies, which include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have the potential to alter the course of type 2 diabetes and associated CVD complications. Advantages of these therapies include glucose-dependent enhancement of insulin secretion, infrequent instances of hypoglycemia, weight loss with GLP-1 receptor agonists, weight maintenance with DPP-IV inhibitors, decreased blood pressure, improvements in dyslipidemia, and potential beneficial effects on CV function.Keywords: cardiovascular disease, glucose control, GLP-1 receptor agonists, DPP-IV inhibitorsSchwartz SDove Medical PressarticleType 2 Diabetesdiabetes treatmentincretin-based therapiesglucose controlGLP-1Cardiovascular diseaseSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 227-242 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Type 2 Diabetes diabetes treatment incretin-based therapies glucose control GLP-1 Cardiovascular disease Specialties of internal medicine RC581-951
spellingShingle	Type 2 Diabetes diabetes treatment incretin-based therapies glucose control GLP-1 Cardiovascular disease Specialties of internal medicine RC581-951 Schwartz S Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
description	Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates of type 2 diabetes mellitus, obesity, and cardiovascular disease (CVD) continue to increase at epidemic proportions. It has become clear that these disease states are not independent but are frequently interrelated. By addressing conditions such as obesity, insulin resistance, stress hyperglycemia, impaired glucose tolerance, and diabetes mellitus, with its micro- and macrovascular complications, a specific treatment strategy can be developed. These conditions can be addressed by early identification of patients at high risk for type 2 diabetes, prompt and aggressive treatment of their hyperglycemia, recognition of the pleiotropic and synergistic benefits of certain antidiabetes agents on CVD, and thus, avoiding potential complications including hypoglycemia and weight gain. Incretin-based therapies, which include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have the potential to alter the course of type 2 diabetes and associated CVD complications. Advantages of these therapies include glucose-dependent enhancement of insulin secretion, infrequent instances of hypoglycemia, weight loss with GLP-1 receptor agonists, weight maintenance with DPP-IV inhibitors, decreased blood pressure, improvements in dyslipidemia, and potential beneficial effects on CV function.Keywords: cardiovascular disease, glucose control, GLP-1 receptor agonists, DPP-IV inhibitors
format	article
author	Schwartz S
author_facet	Schwartz S
author_sort	Schwartz S
title	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_short	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_full	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_fullStr	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_full_unstemmed	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_sort	type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/a245e6dfd42d4d1c8328cb70f5ab4c3a
work_keys_str_mv	AT schwartzs type2diabetesmellitusandthecardiometabolicsyndromeimpactofincretinbasedtherapies
_version_	1718403515399798784

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

Ejemplares similares